Retatrutide, from Soma Corp., is receiving increasing attention as a novel method for obesity management . This unique drug combines the properties of a GLP-1 receptor agonist and a GIP receptor activator , aiming to effectively promote metabolic improvements but also address related metabolic conditions . Early clinical trials have indicated promi